JP4834839B2 - 悪性黒色腫（メラノーマ）の新規な診断キット - Google Patents

悪性黒色腫（メラノーマ）の新規な診断キット Download PDF

Info

Publication number
JP4834839B2
JP4834839B2 JP2006542257A JP2006542257A JP4834839B2 JP 4834839 B2 JP4834839 B2 JP 4834839B2 JP 2006542257 A JP2006542257 A JP 2006542257A JP 2006542257 A JP2006542257 A JP 2006542257A JP 4834839 B2 JP4834839 B2 JP 4834839B2
Authority
JP
Japan
Prior art keywords
sparc
melanoma
gpc3
protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006542257A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2006043362A1 (ja
Inventor
泰治 西村
哲也 中面
義明 生田
Original Assignee
国立大学法人 熊本大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人 熊本大学 filed Critical 国立大学法人 熊本大学
Priority to JP2006542257A priority Critical patent/JP4834839B2/ja
Publication of JPWO2006043362A1 publication Critical patent/JPWO2006043362A1/ja
Application granted granted Critical
Publication of JP4834839B2 publication Critical patent/JP4834839B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2006542257A 2004-10-19 2005-08-09 悪性黒色腫（メラノーマ）の新規な診断キット Expired - Fee Related JP4834839B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006542257A JP4834839B2 (ja) 2004-10-19 2005-08-09 悪性黒色腫（メラノーマ）の新規な診断キット

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004303688 2004-10-19
JP2004303688 2004-10-19
PCT/JP2005/014567 WO2006043362A1 (ja) 2004-10-19 2005-08-09 悪性黒色腫（メラノーマ）の新規な診断キット
JP2006542257A JP4834839B2 (ja) 2004-10-19 2005-08-09 悪性黒色腫（メラノーマ）の新規な診断キット

Publications (2)

Publication Number Publication Date
JPWO2006043362A1 JPWO2006043362A1 (ja) 2008-05-22
JP4834839B2 true JP4834839B2 (ja) 2011-12-14

Family

ID=36202786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006542257A Expired - Fee Related JP4834839B2 (ja) 2004-10-19 2005-08-09 悪性黒色腫（メラノーマ）の新規な診断キット

Country Status (6)

Country Link
US (1) US8017345B2 (https=)
EP (1) EP1813943B1 (https=)
JP (1) JP4834839B2 (https=)
AU (1) AU2005297303B2 (https=)
DE (1) DE602005016831D1 (https=)
WO (1) WO2006043362A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2373055T3 (es) 2005-08-09 2012-01-31 Oncotherapy Science, Inc. Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
AU2007259667B2 (en) * 2006-06-16 2012-06-14 Oncotherapy Science, Inc. SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same
CN102089444A (zh) 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
BRPI0923155A2 (pt) * 2008-12-05 2018-10-23 Abraxis Bioscience Llc scfcs de ligação a sparc
AU2010295324B2 (en) * 2009-09-18 2015-04-30 Abraxis Bioscience, Llc Use of the SPARC microenvironment signature in the treatment of cancer
WO2011137114A1 (en) * 2010-04-26 2011-11-03 Abraxis Bioscience, Llc Sparc binding antibodies and uses thereof
MX2012013874A (es) 2010-06-03 2013-01-24 Abraxis Bioscience Llc Uso de la signatura en el microentorno de sparc en el tratamiento de cancer.
US20130281376A1 (en) * 2010-10-08 2013-10-24 Abraxis Bioscience, Llc Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer
EP2863224A4 (en) * 2012-06-18 2016-05-04 Nat Cancer Ct KIT FOR DIAGNOSIS MALIGNER MELANOME
US20140314697A1 (en) * 2013-04-18 2014-10-23 Corum Inc. Method for Inhibiting Inflammation and Reducing Melanophilin Expression with Glycine Derivatives And the Composition Thereof
US20150005184A1 (en) * 2013-06-28 2015-01-01 Dermtech International Diagnosis of melanoma by nucleic acid analysis
CA3090785A1 (en) 2018-02-14 2019-08-22 John Daniel Dobak Iii Novel gene classifiers and uses thereof in non-melanoma skin cancers
JP2022524641A (ja) 2019-03-26 2022-05-09 ダームテック，インク． 皮膚癌における新規な遺伝子分類子とその使用
US12576166B2 (en) 2020-07-27 2026-03-17 Board Of Regents, The University Of Texas System Contrast agents for detection of enzyme activities based on melanin synthesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064626A2 (en) * 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
AU2003281325A1 (en) * 2002-07-02 2004-01-23 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
WO2004020624A1 (ja) * 2002-08-30 2004-03-11 Kumamoto Technology & Industry Foundation 癌抗原及びその利用
AU2004260083B2 (en) * 2003-07-17 2011-04-07 Pacific Edge Limited Markers for detection of gastric cancer
EP1684076B1 (en) * 2003-10-29 2008-12-31 Kumamoto Technology & Industry Foundation Diagnostic method for malignant melanoma

Also Published As

Publication number Publication date
JPWO2006043362A1 (ja) 2008-05-22
EP1813943B1 (en) 2009-09-23
AU2005297303B2 (en) 2011-11-10
DE602005016831D1 (https=) 2009-11-05
AU2005297303A1 (en) 2006-04-27
US20090111095A1 (en) 2009-04-30
US8017345B2 (en) 2011-09-13
EP1813943A1 (en) 2007-08-01
EP1813943A4 (en) 2007-12-12
WO2006043362A1 (ja) 2006-04-27

Similar Documents

Publication Publication Date Title
JP4594575B2 (ja) がんのマーカーとして使用されるアネキシン類及び自己抗体
CN112362871B (zh) 食管癌的生物标志物及其应用
Jou et al. Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages
JP4834839B2 (ja) 悪性黒色腫（メラノーマ）の新規な診断キット
CN112345755A (zh) 乳腺癌的生物标志物及其应用
KR20120057562A (ko) 피브린 및 피브리노겐 분해 생성물의 검출 및 관련된 제조 방법 및 암의 검출 및 모니터링을 위한 용도
JP2739110B2 (ja) ヒト乳ガンの分析
US8642347B2 (en) Urinary CA125 peptides as biomarkers of ovarian cancer
JP4336898B2 (ja) 悪性黒色腫（メラノーマ）の診断剤
JP4668180B2 (ja) 癌疾患の再発を予測する方法
KR101486548B1 (ko) 나이관련 황반변성 진단용 마커 및 이를 이용한 나이 관련 황반 변성 진단 방법
KR20170029414A (ko) 암을 스크리닝하고 검출하는 방법 및 조성물
US20190204319A1 (en) Method of Screening Breast Cancer by Using Serum WISP1 Level as a Biomarker
CN113030457B (zh) Pcna自身抗体在癌症预测、诊断和预后评估中的应用
CN117233397A (zh) 一种鼻咽癌生物标志物及其应用
JP7432578B2 (ja) がんマーカーおよびその用途
JP2007139742A (ja) 肝細胞癌の素因および／または予後を決定するためのバイオマーカー
KR20120021518A (ko) 간암 진단용 조성물 및 진단방법
JP5358808B2 (ja) 腫瘍マーカー、腫瘍診断キット、腫瘍マーカーの測定方法および腫瘍診断方法
KR101594287B1 (ko) 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트
KR100991289B1 (ko) 유방암 진단용 ａ２―ＨＳ 당단백질에 대한 자가항체마커및 진단키트
JP2000131321A (ja) 膀胱癌患者の予後診断薬
JP2010139293A (ja) 早期癌腫瘍マーカー
CN117129681A (zh) 乳腺癌相关的生物标志物及其应用
JPWO2001020333A1 (ja) 早期癌腫瘍マーカー

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110830

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141007

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141007

Year of fee payment: 3

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

LAPS Cancellation because of no payment of annual fees